Rahul Seth, DO, assistant professor of medicine at Upstate University Hospital, provides recommendations for the treatment of melanoma. For patients with unresectable melanoma, Dr. Seth recommends a combination of nivolumab and ipilimumab followed by nivolumab or pembrolizumab, with the addition of a BRAF/MEK inhibitor for patients with BRAF V600 mutations. For adjuvant therapy, Dr. Seth suggests patients enroll in a clinical trial. The unresectable melanoma protocol is also useful for mucosal noncutaneous melanoma, while a clinical trial is the best option for those with uveal melanoma. Dr. Seth also recommends patients enroll in a clinical trial for neoadjuvant therapy. Click here to learn more.